NSE: PFIZER | BSE: 500680

Mid-range Performer

Download real time

4880.60 -19.40 (-0.40%)

6,548 NSE+BSE Volume

NSE 07 Aug, 2026 3:31 PM (IST)

22,327.6

Market Cap

High in industry

Beta 1Year

Very Low volatility

Pfizer Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for PFIZER, BSE:500680 Pfizer Ltd.

Search Inside the pdf :

Pfizer Ltd.

29 Jul 2026

4880.60

-0.40%

Pfizer Ltd

Buy: Pfizer Ltd.

Target

ICICI Direct

Recent launches, new SKUs to drive numbers : Pfizer collectively addresses 15 therapy areas in the domestic formulations with a portfolio of more than 125 products that include therapeutics & vaccines. The company has been continuously restructuring its portfolio to...

ICICI Direct increased Buy price target of Pfizer Ltd. to 5815.0 on 29 Jul, 2026.

Pfizer Ltd.

28 Jul 2026

4880.60

-0.40%

Steady quarter; cost rationalisation boosts margins

Buy: Pfizer Ltd.

ICICI Securities Limited

Pfizer’s Q1FY27 performance was in line with our expectations. Revenue growth of 8.3% YoY is likely to be supported by traction in Zavicefta and Eliquis. In Dec’25, Pfizer out-licensed four brands — Corex Dx and Corex LS, Dolonex and Neksium — to Cipla.

ICICI Direct increased Buy price target of Pfizer Ltd. to 5815.0 on 29 Jul, 2026.

Pfizer Ltd.

10 Jul 2026

4880.60

-0.40%

Pfizer FY26 ARA: New launches and collaborations to boost growth

Buy: Pfizer Ltd.

Target

ICICI Securities Limited

Pfizer, in its FY26 annual report, has highlighted key brands like Prevenar-13, Eliquis and Zavicefta as primary revenue growth drivers.

Pfizer Ltd. is trading above all available SMAs

Pfizer Ltd.

13 May 2026

4880.60

-0.40%

Pfizer Ltd

Buy: Pfizer Ltd.

Target

ICICI Direct

FY26 growth reflects focus on structural changes formulations with a portfolio of more than 125 products that include therapeutics & vaccines. The company has been continuously restructuring its portfolio to...

Number of FII/FPI investors decreased from 174 to 153 in Jun 2026 qtr

Pfizer Ltd.

10 Feb 2026

4880.60

-0.40%

Pfizer Ltd

Buy: Pfizer Ltd.

Recommendation Target

ICICI Direct

Q3FY26 - Strong Revenue growth and margins- Revenues grew ~20% to ~ 645 crore, driven by growth in power brands such as Mucaine (Antacid), Eliquis (CVS), among others. Brands such as Minipress XL (CVS), and Becosules (VMS) also registered moderate growth. On the other hand, there was a de-growth in other power brands such as Corex DX (cough syrup), Dolonex (pain management) and Prevnar 13 (pneumococcal vaccine). EBITDA grew 56% with a strong margin expansion of 824 bps YoY to 35.4%. GPM grew by 169 bps to 65.2%. PAT grew 11% with a...

Pfizer Ltd. is trading above all available SMAs

Pfizer Ltd.

14 Nov 2025

4880.60

-0.40%

Growth momentum accelerating

Buy: Pfizer Ltd.

Recommendation Target

ICICI Securities Limited

Pfizer’s Q2FY26 revenue grew at a faster pace of 9.1% YoY, surpassing IPM growth of ~8%. Rebound in growth across key brands has helped the company grow faster in the otherwise prevalent sluggish growth scenario for acute therapies.

Pfizer Ltd. is trading above all available SMAs

Pfizer Ltd.

31 Oct 2023

4880.60

-0.40%

Margins balm the pain of a weak season

Accumulate: Pfizer Ltd.

ICICI Securities Limited

Pfizer’s Q2FY24 revenues declined by 9.8%, marred by a weak season for acute products and the recall of three key brands Magnex, Magnamycin and Zoysn. Gross margins contracted 40bps YoY, but recovered 503bps QoQ to 64.4% as the impact of mandated price cuts on NLEM products was partially offset by better product mix.

ICICI Direct increased Buy price target of Pfizer Ltd. to 5815.0 on 29 Jul, 2026.

Pfizer Ltd.

18 Aug 2023

4880.60

-0.40%

Earnings hit by product recall

Accumulate: Pfizer Ltd.

Target

ICICI Securities Limited

Pfizer’s Q1FY24 performance was marred by recall of three key brands - Magnex, Magnamycin and Zoysn. These had annual sales of INR 1.4bn in FY23. Gross margin contracted 420bps YoY at 59.4%, also impacted by mandated price cut on NLEM products.

Number of FII/FPI investors decreased from 174 to 153 in Jun 2026 qtr

Pfizer Ltd.

17 May 2023

4880.60

-0.40%

Power brands help restore revenue traction

Accumulate: Pfizer Ltd.

Recommendation Target

ICICI Securities Limited

Q4FY23 marked a turnaround in Pfizer’s performance as the declining revenue trend (down 7% in FY23) was arrested in Q4, which saw a 4% YoY rise. The turnaround was driven by traction in key brands such as Magnex, Corex DX, Dolonex, Minipress XL and Prevenar-13.